A Phase 3 Multicenter Open-Label Randomized Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Brief description of study
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin resistant strains of Staphylococcus aureus
Clinical Study Identifier: s16-01263
ClinicalTrials.gov Identifier: NCTs16-01263
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
